• Sponsored Content

Unlocking the Potential of CHO Cells: Advancing Bioproduction with Next-Generation Vector Design and Model-Guided Cell Line Development

BPI Contributor

September 7, 2023

20 Min View
Unlocking the Potential of CHO Cells: Advancing Bioproduction with Next-Generation Vector Design and Model-Guided Cell Line Development

Date: Sep 7, 2023

Duration: 20 Min

This webcast features: Scott Estes, Head of Cell Line Development, Asimov.

Traditional cell line development to support bioprocessing has typically relied on a “one-size-fits-all” vector, which can streamline development, but in most cases can lead to suboptimal expression levels, particularly for complex multi-specific molecular architectures. The commercial consequences are increased cost of goods, reduced facility flexibility, and in the worst case the inability to support commercial demand.

In this webinar, Asimov presents their CHO Edge platform, which builds on the current state of the art for CLD by integrating expanded genetic tools with data driven models. Incorporating a GS knock-out CHO host, a hyperactive transposase, a library of >2000 characterized genetic elements, and advanced computational tools, the CHO Edge platform empowers researchers to explore the vector design space and achieve greater expression efficiency and quality.

Join us to learn how you can unlock the potential of a flexible and data-driven approach to vector design in your cell line development, and discover how it can significantly enhance expression in CHO cells.

Key Takeaways:

  • Versatile vector design: Learn how the Asimov CHO Edge platform integrates multiple components to allow for the exploration of vector design space. Discover how this flexibility leads to enhanced expression efficiency and quality.

  • Precision control over protein production: Understand how the platform enables fine-tuning of heavy/light chain expression and GS selection, giving researchers precise control over protein production for a range of therapeutic molecules, including monoclonal antibodies and bispecific antibodies.

  • Data-driven optimization: Discover how model guided CLD and process development can be used to enhance performance further.

Just fill out the form below to view the recorded webcast now.

You May Also Like